Fulcrum Therapeutics to merge with Slate Medicines in reverse merger with $245M financing
Fulcrum Therapeutics announced an all-stock reverse merger with privately held Slate Medicines, accompanied by a $245 million private placement. The deal follows Fulcrum's discontinuation of its lead drug development after regulatory setbacks.
